In focus · trending topic

RDEB

18 stories · following the connections

Abeona Therapeutics Announces Upcoming Presentations

By Nasdaq OMXMay 8, 2018, 12:15 PM UTC

Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa

By Nasdaq OMXJan 29, 2018, 1:45 PM UTC

Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102

By Nasdaq OMXSep 28, 2017, 12:32 PM UTC

Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa

By Nasdaq OMXJul 18, 2017, 12:05 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 25, 2017, 12:10 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 25, 2017, 12:10 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 25, 2017, 12:10 PM UTC

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

By Nasdaq OMXMay 25, 2017, 12:10 PM UTC